Phase 1 FORAGER-1 trial demonstrates LOXO-435's superior safety profile with 41% objective response rate in metastatic urothelial cancer patients with FGFR3 alterations.
Pfizer will showcase over 20 abstracts at ASCO GU 2025, including pivotal Phase 3 TALAPRO-2 trial results demonstrating significant overall survival benefits for TALZENNA-XTANDI combination in prostate cancer.
The FDA has cleared Tyra Biosciences' IND application for TYRA-300, allowing a Phase 2 trial in low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.